Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
March 17, 2026Pamplona/MadridIn recruitment
D7029C00001 A Phase III, randomized, open-label, sponsor-blinded, multicenter clinical trial of rilvegostomig in combination with bevacizumab, with or without tremelimumab, as first-line treatment in patients with advanced hepatocellular carcinoma.
The objective of this clinical trial is to gather more information on the efficacy and safety of Rilvegostomig in combination with bevacizumab, with or without tremelimumab, compared to the standard of care (atezolizumab in combination with bevacizumab), as well as to better understand the disease being studied and the associated health issues -
March 16, 2026Pamplona/MadridIn recruitmentEarly phase
GEM-PLASMACAR Clinical trial to evaluate the safety and efficacy of ARI0002h, a BCMA-targeted CAR-T cell therapy, for the initial treatment of patients with primary plasma cell leukemia
The GEM-PLASMACAR study is a clinical trial for people with a recent diagnosis of primary plasma cell leukemia (pPCL). In this study, we aim to determine whether ARI0002h cells are safe and effective in eliminating the disease. -
March 16, 2026PamplonaIn recruitmentEarly phase
68284528MMY2012 A Phase 2 clinical trial with multiple cohorts to better characterize the efficacy and safety of ciltacabtagene autoleucel
The aim of this study is to learn more about how cilta-cel works and its safety in treating patients with multiple myeloma, a type of cancer. In this study, there will be different groups of patients known as cohorts. -
March 16, 2026PamplonaIn recruitmentEarly phase
20180257 Clinical trial of subcutaneous blinatumomab for the treatment of adults with refractory or relapsed B-precursor acute lymphoblastic leukemia
The purpose of this study is to determine which doses of blinatumomab (the study drug) administered by subcutaneous injection (just under the skin) are safe to give to patients. This study will also determine whether blinatumomab is safe and tolerable (has good or bad effects) at these doses and how blinatumomab works inside the body when administered in this way. -
March 16, 2026Pamplona/MadridIn recruitment
TranspoCALL19 A Phase I/IIa clinical trial of an infusion of autologous peripheral blood T cells that have been expanded and transduced using Sleeping Beauty technology to express a chimeric antigen receptor with anti-CD19 specificity.
The TranspoCALL19 study is a clinical trial for people with B-cell acute lymphoblastic leukemia who have received standard treatments but still require further treatment for their disease. -
March 9, 2026PamplonaIn recruitment
YO45758 Ensayo de RO7673396 en monoterapia y en combinación con otros tratamientos antineoplásicos en pacientes con tumores sólidos avanzados, portadores de una o más mutaciones en ras.
Este estudio está diseñado para evaluar la actividad de RO7673396 como monoterapia (parte A) y en combinación con otros tratamientos contra el cáncer (partes B y C) -
March 9, 2026PamplonaIn recruitmentEarly phase
ZWI-ZW251-101 Ensayo de ZW251, un nuevo conjugado anticuerpo-fármaco dirigido al glipicano 3, en participantes con tumores sólidos avanzados, incluido el carcinoma hepatocelular.
El objetivo principal de este estudio es comprobar la seguridad y la tolerancia del ZW251, comprender cómo el organismo procesa el ZW251 y cómo afecta el ZW251 al CHC o los TCG avanzados o metastásicos. -
March 4, 2026PamplonaIn recruitmentEarly phase
VVD-130037-01 Clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of VVD-130037.
El objetivo de esta parte 2 de ampliación de la dosis del ensayo clínico es conocer la seguridad, tolerabilidad y eficacia de VVD-130037 en sujetos con cáncer de pulmón no microcítico (CPNM) de células escamosas con mutaciones NRF2 y/o CUL3 que se ha diseminado a pesar de haber recibido todo el estándar de atención disponible. VVD-130037 es un medicamento en investigación, lo que significa que no está aprobado por ninguna autoridad sanitaria/competente. -
March 4, 2026Pamplona/MadridIn recruitment
D7770C00001 Modular, open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of AZD2962, as monotherapy and in combination with other agents, in participants with hematologic malignancies.
Estamos realizando este estudio para obtener más información sobre AZD2962 y conocer mejor la enfermedad estudiada y los problemas de salud que conlleva. AZD2962 es un inhibidor eficaz de la cinasa 4 del receptor de interleucina 1 (IRAK4, en sus siglas inglesas), lo que significa que disminuye el efecto de IRAK4. La cinasa IRAK4 desempeña un papel clave en las vías inflamatorias (la inflamación es la respuesta natural del organismo a una lesión, infección o irritación), que provocan algunas de l... -
March 2, 2026Pamplona/MadridIn recruitmentEarly phase